Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Chupradit K, Thongsin N, Tayapiwatana C, Wattanapanitch M. A precise gene delivery approach for human induced pluripotent stem cells using Cas9 RNP complex and recombinant AAV6 donor vectors. PLoS One 2022;17:e0270963. [PMID: 35797389 PMCID: PMC9262223 DOI: 10.1371/journal.pone.0270963] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 06/17/2022] [Indexed: 11/18/2022] Open

For:	Chupradit K, Thongsin N, Tayapiwatana C, Wattanapanitch M. A precise gene delivery approach for human induced pluripotent stem cells using Cas9 RNP complex and recombinant AAV6 donor vectors. PLoS One 2022;17:e0270963. [PMID: 35797389 PMCID: PMC9262223 DOI: 10.1371/journal.pone.0270963] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 06/17/2022] [Indexed: 11/18/2022] Open

Number

Cited by Other Article(s)

Hammad R, Alzubi J, Rhiel M, Chmielewski KO, Mosti L, Rositzka J, Heugel M, Lawrenz J, Pennucci V, Gläser B, Fischer J, Schambach A, Moritz T, Lachmann N, Cornu TI, Mussolino C, Schäfer R, Cathomen T. CRISPR-Cas12a for Highly Efficient and Marker-Free Targeted Integration in Human Pluripotent Stem Cells. Int J Mol Sci 2024;25:985. [PMID: 38256061 PMCID: PMC10816062 DOI: 10.3390/ijms25020985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2023] [Revised: 01/04/2024] [Accepted: 01/09/2024] [Indexed: 01/24/2024] Open

Affiliation(s)

Ruba Hammad Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany Freiburg iPS Core Facility, Medical Center—University of Freiburg, 79106 Freiburg, Germany PhD Program, Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany
Jamal Alzubi Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany
Manuel Rhiel Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany
Kay O. Chmielewski Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany PhD Program, Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany
Laura Mosti Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany
Julia Rositzka Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany
Marcel Heugel Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany
Jan Lawrenz Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany
Valentina Pennucci Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany
Birgitta Gläser Institute of Human Genetics, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (B.G.); (J.F.)
Judith Fischer Institute of Human Genetics, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (B.G.); (J.F.) Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany
Axel Schambach Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany; (A.S.); (T.M.) REBIRTH Center for Regenerative and Translational Medicine, Hannover Medical School, 30625 Hannover, Germany;
Thomas Moritz Institute for Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany; (A.S.); (T.M.) REBIRTH Center for Regenerative and Translational Medicine, Hannover Medical School, 30625 Hannover, Germany;
Nico Lachmann REBIRTH Center for Regenerative and Translational Medicine, Hannover Medical School, 30625 Hannover, Germany; Department of Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, 30625 Hannover, Germany Biomedical Research in Endstage and Obstructive Lung Disease, German Center for Lung Research, Hannover Medical School, 30625 Hannover, Germany Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, 30625 Hannover, Germany Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), 30625 Hannover, Germany
Tatjana I. Cornu Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany
Claudio Mussolino Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany
Richard Schäfer Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany Freiburg iPS Core Facility, Medical Center—University of Freiburg, 79106 Freiburg, Germany Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany
Toni Cathomen Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; (R.H.); (J.A.); (M.R.); (K.O.C.); (L.M.); (J.R.); (M.H.); (V.P.); (T.I.C.); (C.M.); (R.S.) Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

Collapse

Validation of Promoters and Codon Optimization on CRISPR/Cas9-Engineered Jurkat Cells Stably Expressing αRep4E3 for Interfering with HIV-1 Replication. Int J Mol Sci 2022;23:ijms232315049. [PMID: 36499376 PMCID: PMC9738563 DOI: 10.3390/ijms232315049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Revised: 11/15/2022] [Accepted: 11/27/2022] [Indexed: 12/05/2022] Open

Abstract

Persistent and efficient therapeutic protein expression in the specific target cell is a significant concern in gene therapy. The controllable integration site, suitable promoter, and proper codon usage influence the effectiveness of the therapeutic outcome. Previously, we developed a non-immunoglobulin scaffold, alpha repeat protein (αRep4E3), as an HIV-1 RNA packaging interference system in SupT1 cells using the lentiviral gene transfer. Although the success of anti-HIV-1 activity was evidenced, the integration site is uncontrollable and may not be practical for clinical translation. In this study, we use the CRISPR/Cas9 gene editing technology to precisely knock-in αRep4E3 genes into the adeno-associated virus integration site 1 (AAVS1) safe harbor locus of the target cells. We compare the αRep4E3 expression under the regulation of three different promoters, including cytomegalovirus (CMV), human elongation factor-1 alpha (EF1α), and ubiquitin C (UbC) promoters with and without codon optimization in HEK293T cells. The results demonstrated that the EF1α promoter with codon-optimized αRep4E3mCherry showed higher protein expression than other promoters with non-optimized codons. We then performed a proof-of-concept study by knocking in the αRep4E3mCherry gene at the AAVS1 locus of the Jurkat cells. The results showed that the αRep4E3mCherry-expressing Jurkat cells exhibited anti-HIV-1 activities against HIV-1NL4-3 strain as evidenced by decreased capsid (p24) protein levels and viral genome copies as compared to the untransfected Jurkat control cells. Altogether, our study demonstrates that the αRep4E3 could interfere with the viral RNA packaging and suggests that the αRep4E3 scaffold protein could be a promising anti-viral molecule that offers a functional cure for people living with HIV-1.

Collapse